Prospects for Improving Brain Function in Individuals with Down Syndrome
@article{Costa2013ProspectsFI, title={Prospects for Improving Brain Function in Individuals with Down Syndrome}, author={A. Costa and J. J. Scott-McKean}, journal={CNS Drugs}, year={2013}, volume={27}, pages={679-702} }
Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there have been several new promising studies on pharmacological agents capable of rescuing learning/memory deficits seen in mouse models of DS. Here, we will review the available mouse… CONTINUE READING
Paper Mentions
Interventional Clinical Trial
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the
study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto… Expand
Conditions | Down Syndrome, Intellectual Disability |
---|---|
Intervention | Drug |
54 Citations
Timing of therapies for Down syndrome: the sooner, the better
- Medicine
- Front. Behav. Neurosci.
- 2015
- 57
- PDF
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.
- Psychology, Medicine
- Current Alzheimer research
- 2016
- 23
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
- Psychology, Medicine
- Neurobiology of Disease
- 2015
- 30
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome
- Psychology, Medicine
- Neuroscience
- 2016
- 33
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?
- Psychology, Medicine
- Neurogenesis
- 2017
- 7
Pharmacological Rescue of Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome
- Psychology
- 2014
- 1
- PDF
Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome
- Biology, Medicine
- Brain Research Bulletin
- 2018
- 5
- PDF
References
SHOWING 1-10 OF 218 REFERENCES
On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
- Psychology, Medicine
- Developmental Neuroscience
- 2011
- 40
Synaptic and cognitive abnormalities in mouse models of down syndrome: Exploring genotype‐phenotype relationships
- Biology, Medicine
- The Journal of comparative neurology
- 2007
- 172
- Highly Influential
Rescue of Synaptic Failure and Alleviation of Learning and Memory Impairments in a Trisomic Mouse Model of Down Syndrome
- Psychology, Medicine
- Journal of neuropathology and experimental neurology
- 2011
- 28
- Highly Influential
- PDF
Function and regulation of Dyrk1A: towards understanding Down syndrome
- Biology, Medicine
- Cellular and Molecular Life Sciences
- 2009
- 145
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome
- Psychology, Medicine
- The Journal of Neuroscience
- 2010
- 158
- PDF
Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
- Psychology, Medicine
- Translational Psychiatry
- 2012
- 67
- PDF
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: Activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer
- Psychology, Medicine
- Neurobiology of Disease
- 2011
- 100
- PDF
Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model
- Biology, Medicine
- Experimental Neurology
- 2009
- 110
Hippocampal Long-Term Potentiation Suppressed by Increased Inhibition in the Ts65Dn Mouse, a Genetic Model of Down Syndrome
- Psychology, Medicine
- The Journal of Neuroscience
- 2004
- 412
- PDF